Citation: Immunotherapy. 12(12):861-867, 2020 Aug..Journal: Immunotherapy.Published: ; 2020ISSN: 1750-743X.Full author list: Zaemes J; Alzeer A; Villa K; Atkins M.UI/PMID: 32640856.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Washington Hospital CenterDepartment(s): Medicine/Internal Medicine | PathologyActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access onlineDigital Object Identifier: https://dx.doi.org/10.2217/imt-2020-0139 (Click here)Abbreviated citation: Immunotherapy. 12(12):861-867, 2020 Aug.Abstract: Background: Despite the profound effect that checkpoint inhibitors and BRAF/MEK inhibitors have had on survival in patients with metastatic melanoma, treatment options remain limited for those who demonstrate poor response or develop resistance to these modalities. The prospect of tumor sensitization to these treatments is therefore an attractive one. Results: We describe the case of a patient who developed a sustained response to trametinib and pembrolizumab, despite prior resistance to both these therapies, after receiving treatment with a CDK4/6 inhibitor. Discussion: We further outline the preclinical data supporting a possible role for the use of CDK4/6 inhibitors in tumor sensitization to immunotherapy.
